Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 23,042 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.43, for a total value of $32,950.06. Following the completion of the transaction, the chief executive officer now directly owns 844,209 shares of the company's stock, valued at $1,207,218.87. This trade represents a 2.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Zhenya Lindgardt also recently made the following trade(s):
- On Tuesday, June 10th, Zhenya Lindgardt sold 3,344 shares of Sera Prognostics stock. The shares were sold at an average price of $1.48, for a total value of $4,949.12.
- On Thursday, May 8th, Zhenya Lindgardt sold 9,406 shares of Sera Prognostics stock. The stock was sold at an average price of $2.44, for a total value of $22,950.64.
Sera Prognostics Stock Performance
SERA traded up $0.28 during trading on Thursday, reaching $1.78. 1,214,069 shares of the company's stock were exchanged, compared to its average volume of 150,965. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13. The firm has a market capitalization of $67.06 million, a PE ratio of -1.80 and a beta of 0.71. The company's fifty day moving average price is $2.53 and its 200-day moving average price is $4.69.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.06 million. Research analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Wall Street Zen cut shares of Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th.
Read Our Latest Stock Report on Sera Prognostics
Hedge Funds Weigh In On Sera Prognostics
Several institutional investors and hedge funds have recently added to or reduced their stakes in SERA. BNP Paribas Financial Markets bought a new position in Sera Prognostics during the fourth quarter worth $28,000. Rhumbline Advisers boosted its stake in Sera Prognostics by 10.6% in the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company's stock valued at $294,000 after acquiring an additional 3,468 shares during the last quarter. Sanders Morris Harris LLC raised its position in shares of Sera Prognostics by 4.0% in the first quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company's stock valued at $347,000 after purchasing an additional 3,600 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Sera Prognostics by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company's stock worth $661,000 after acquiring an additional 4,115 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Sera Prognostics by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company's stock worth $499,000 after acquiring an additional 4,670 shares during the period. Institutional investors own 54.64% of the company's stock.
About Sera Prognostics
(
Get Free Report)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Further Reading
Before you consider Sera Prognostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sera Prognostics wasn't on the list.
While Sera Prognostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
